India started its inaugural phase 3 clinical trial for the DengiAll dengue vaccine, developed by Panacea Biotec. The trial will include 10,335 healthy adults at 19 sites across various states, supported by the Indian Council of Medical Research. Health Minister J P Nadda called it a significant step in India's ongoing battle against dengue.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.